Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 7/20 | 0.69 |
| ▸ | NPY2R | P49146 | 7/20 | 0.68 |
| ▸ | NPY4R | P50391 | 7/20 | 0.68 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.68 |
| ▸ | NPY1R | P25929 | 5/20 | 0.68 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.68 |
| ▸ | TFPI | P10646 | 4/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29895442 | 0.93 | CALCR (0.73) | PTH1R | |
| SCHEMBL6437853 | 0.93 | CALCR (0.73) | PTH1R | |
| SCHEMBL31139067 | 0.91 | CALCR (0.62) | PTH1RNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29939518 | 0.90 | CALCR (0.58) | PTH1RNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29977603 | 0.90 | NPY2R (0.69) | PTH1RNPY2RNPY4RNPY5RNPY1R | |
| Isracidin SCHEMBL29668326 | 0.89 | NPY2R (0.70) | PTH1RNPY2RNPY4RNPY5RNPY1R | |
| Scyllatoxin SCHEMBL29388554 | 0.89 | PTH1R (0.74) | PTH1R | |
| SCHEMBL30887555 | 0.87 | CALCR (0.66) | NPY2RNPY4RNPY5RNPY1RCXCR4 | |
| SCHEMBL9979655 | 0.87 | NPY2R (0.69) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL15669203 | 0.86 | NPY2R (0.74) | NPY2RNPY4RNPY5RNPY1RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096779-A2 | METHODS OF TREATMENT WITH A MYOSIN INHIBITOR USING PROTEIN LEVELS | BRISTOL MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | claimed |
| CN-111527410-B | Standard for BNP measurement | 盐野义制药株式会社 | 2024-09-10 | — | — | CN | claimed |
| CN-116814608-A | Kit for extracting staphylococcus aureus DNA by magnetic bead method and extraction method thereof | 山东博弘基因科技有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-110339346-B | External skin preparation composition | IGISU株式会社 | 2023-06-27 | — | — | CN | claimed |
| EP-3734287-B1 | REFERENCE STANDARD FOR BNP MEASUREMENT | SHIONOGI & CO (JP) | 2023-05-17 | — | — | EP | claimed |
| US-11561230-B2 | Reference standard for BNP measurement | SHIONOGI & CO., LTD. (JP) | 2023-01-24 | — | — | US | claimed |
| US-12601746-B2 | Biomarkers of renal injury | UNIVERSITY OF PITTSBURGH- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-12590131-B2 | Antimicrobial peptides with alpha-core helices | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER (US) | 2026-03-31 | — | — | US | disclosed |
| US-12590975-B2 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | BIOMERIEUX, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12560616-B2 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | BIOMERIEUX, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250283153-A1 | MULTIPLEX METHODS OF DETECTING MOLECULES USING NANOPORES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-09-11 | — | — | US | disclosed |
| EP-3621632-B1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-20220099687-A1 | POLYCLONAL-MONOCLONAL ELISA ASSAY FOR DETECTING N-TERMINUS PRO-BNP | NEXUS DX INC (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3974836-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | Astute Medical, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-114207436-A | Methods for assessing and treating renal injury based on C-C motif chemokine ligand 14 measurements | 机敏医药股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-111848776-B | Polyethylene glycol modified rhBNP and preparation method thereof | 江苏璟泽生物医药有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3968022-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | Astute Medical, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11262363-B2 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | ASTUTE MEDICAL, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| CN-114088950-A | Methods and compositions for evaluating and treating renal injury and renal failure based on C-C motif chemokine ligand 14 measurements | 机敏医药股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12560616-B2 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | CHI3L1, CHI3L2, CHIT1 | PTH1R 766/4885NPY2R 2599/4885NPY4R 3742/4885 |
| US-12590975-B2 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | IGFBP6, IGFBP1, IGFBP3 | PTH1R 201/4885NPY2R 1392/4885NPY4R 1501/4885 |
| US-12590131-B2 | Antimicrobial peptides with alpha-core helices | VIP, HAMP, HM13 | PTH1R 127/4885NPY2R 998/4885NPY4R 781/4885 |
| US-11561230-B2 | Reference standard for BNP measurement | NPPA, NPR1, NPR3 | PTH1R 16/4885NPY2R 336/4885NPY4R 391/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | PTH1R 3702/4885NPY2R 3500/4885NPY4R 3663/4885 |
| US-12601746-B2 | Biomarkers of renal injury | CD44, HDGF, PLAUR | PTH1R 266/4885NPY2R 1629/4885NPY4R 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.